ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 65 filers reported holding ASCENDIS PHARMA A/S in Q4 2017. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $16,972,000 | -46.4% | 144,194 | -71.5% | 0.65% | -48.6% |
| Q4 2018 | $31,644,000 | +39.6% | 505,098 | +57.8% | 1.27% | +56.0% |
| Q3 2018 | $22,675,000 | -29.3% | 320,000 | -33.7% | 0.81% | -28.0% |
| Q2 2018 | $32,094,000 | +1.7% | 482,467 | 0.0% | 1.13% | +3.1% |
| Q1 2018 | $31,553,000 | -0.2% | 482,467 | -38.9% | 1.09% | -12.1% |
| Q4 2017 | $31,607,000 | +2.6% | 789,000 | -7.2% | 1.24% | -10.4% |
| Q3 2017 | $30,813,000 | +164.6% | 850,000 | +102.6% | 1.39% | +123.5% |
| Q2 2017 | $11,644,000 | -55.2% | 419,453 | -54.9% | 0.62% | -38.1% |
| Q1 2017 | $26,018,000 | +22.4% | 929,226 | -11.5% | 1.00% | +14.8% |
| Q4 2016 | $21,252,000 | +5659.3% | 1,050,000 | +4933.8% | 0.87% | +7183.3% |
| Q2 2015 | $369,000 | -89.4% | 20,859 | -89.6% | 0.01% | -89.3% |
| Q1 2015 | $3,470,000 | – | 200,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |